Abbott Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V
Pooled Analysis of Nearly 7,000 Patients Confirms Outstanding Performance of XIENCE V, Includes Thousands of Patients with Complex Disease. Independent Analysis Confirms Low Rate of Stent Thrombosis for XIENCE V (0.7 Percent). In Clinical Trials, XIENCE V Has Been Studied in More Than 30,000 Patients orldwide.
- (1888PressRelease) April 05, 2011 - New Orleans - A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's (NYSE: ABT) market-leading XIENCE V Everolimus Eluting Coronary Stent System. As part of the analysis of all four trials, two-year results on the safety and efficacy of XIENCE V compared to TAXUS Liberte and TAXUS Express2 Paclitaxel-Eluting Coronary Stent Systems (TAXUS) were presented at the American College of Cardiology's (ACC) 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.
In a presentation given by Dean J. Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center in Cincinnati, Ohio, predictors of artery re-blockage, cardiac death or heart attack were evaluated out to two years in nearly 7,000 patients from the SPIRIT II, III, IV and COMPARE clinical trials. The data demonstrated that use of XIENCE V resulted in significantly lower clinical event rates following a stent procedure. In the pooled analysis, XIENCE V demonstrated a 36 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (7.3 percent for XIENCE V versus 11.1 percent for TAXUS, p-value
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam